Skip to Content
Merck
CN

C4024

Carbamazepine

≥98% (HPLC), powder, sodium channel inhibitor

Synonym(s):

5H-Dibenz[b,f]azepine-5-carboxamide

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C15H12N2O
CAS Number:
298-46-4
Molecular Weight:
236.27
UNSPSC Code:
12352200
eCl@ss:
34051404
PubChem Substance ID:
57654002
NACRES:
NA.77
EC Number:
206-062-7
MDL number:
MFCD00005073

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Carbamazepine, powder

SMILES string

NC(=O)N1c2ccccc2C=Cc3ccccc13

InChI

1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)

InChI key

FFGPTBGBLSHEPO-UHFFFAOYSA-N

form

powder

mp

191-192 °C (lit.)

solubility

45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 29 mg/mL
H2O: insoluble
ethanol: soluble
propylene glycol: soluble

originator

Novartis

storage temp.

2-8°C

Quality Level

100

Gene Information

human ... BZRAP1(9256), GABRA1(2554), GABRA2(2555), GABRA3(2556), GABRA4(2557), GABRA5(2558), GABRA6(2559), GABRB1(2560), GABRB2(2561), GABRB3(2562), PRNP(5621), SCN10A(6336), SCN11A(11280), SCN1A(6323), SCN2A(6326), SCN3A(6328), SCN4A(6329), SCN5A(6331), SCN7A(6332), SCN8A(6334), SCN9A(6335)
rat ... Scn2a1(24766), Scnn1a(25122), Scnn1g(24768), Slc6a1(79212)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Carbamazepine has been used to investigate its behavior in wastewater treatment and during groundwater infiltration. It has also been used to find out its effects on spontaneous seizures in rats.

Biochem/physiol Actions

Anticonvulsant; ligand for the GABAA receptor benzodiazepine modulatory site. Sodium channel inhibitor.
Carbamazepine is considered as a safe antiepileptic drug. It decreases the multiple drug therapy and maintains a better control of epilepsy.

Features and Benefits

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Repr. 1A - Resp. Sens. 1 - Skin Sens. 1A - STOT SE 3

target_organs

Central nervous system

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
MKCZ4253
MKCW3471
MKCT1147
MKCS8041
MKCT3831

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Effect of antiepileptic drugs on spontaneous seizures in epileptic rats
Nissinen J and Pitkanen A
Epilepsy Research, 73(2), 181-191 (2007)
Opeyemi Samson Osuntokun et al.
Toxicology reports, 7, 1592-1596 (2020-12-12)
This study investigated the effects of co-administration of carbamazepine (CBZ) with grape (Vitis vinifera) seed methanolic extract (GSME) on liver toxicity. Thirty-five male rats (145-155 g) were randomized into 5 groups (n = 7) and administered with propylene glycol (PG
Carbamazepine as a possible anthropogenic marker in the aquatic environment: investigations on the behaviour of carbamazepine in wastewater treatment and during groundwater infiltration
Clara M, et al.
Water Research, 38(4), 947-954 (2004)
Role of carbamazepine in reducing polypharmacy in epilepsy
Maheshwari MC and Padmini R
Acta Neurologica Scandinavica, 64(1), 22-28 (1981)
J P Johnson et al.
eLife, 11 (2022-03-03)
NBI-921352 (formerly XEN901) is a novel sodium channel inhibitor designed to specifically target NaV1.6 channels. Such a molecule provides a precision-medicine approach to target SCN8A-related epilepsy syndromes (SCN8A-RES), where gain-of-function (GoF) mutations lead to excess NaV1.6 sodium current, or other
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service